T. Rowe Price Associates, Inc. 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | T. Rowe Price Associates, Inc. | 4,663,785 2.900% | -2,718,420 (-36.82%) | Filing |